{"filing":{"accession_number":"0001829126-26-010493","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626010493/neonctechnologies_8k.htm"},"events":[{"id":35500,"run_id":32699,"accession_number":"0001829126-26-010493","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NeOnc announced a scheduled FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, to discuss Phase 2 study design and regulatory pathways. This is a material regulatory milestone for a clinical-stage biopharmaceutical company, as FDA feedback on trial design and potential accelerated approval pathways directly affects the company's development strategy and commercial prospects. The disclosure does not fit specific categories (not earnings, M\u0026A, impairment, litigation, or debt-related), making it an operational/strategic regulatory event.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39568,"accession_number":"0001829126-26-010493","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeOnc announced a scheduled FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, to discuss Phase 2 study design and regulatory pathways. This is a material regulatory milestone for a clinical-stage biopharmaceutical company, as FDA feedback on trial design and potential accelerated approval pathways directly affects the company's development strategy and commercial prospects. The disclosure does not fit specific categories (not earnings, M\u0026A, impairment, litigation, or debt-related), making it an operational/strategic regulatory event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:05:43.388437+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39568,"accession_number":"0001829126-26-010493","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeOnc announced a scheduled FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, to discuss Phase 2 study design and regulatory pathways. This is a material regulatory milestone for a clinical-stage biopharmaceutical company, as FDA feedback on trial design and potential accelerated approval pathways directly affects the company's development strategy and commercial prospects. The disclosure does not fit specific categories (not earnings, M\u0026A, impairment, litigation, or debt-related), making it an operational/strategic regulatory event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:05:43.388437+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-09-28"}]}